Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma. ZUMA-5 is a single-arm, multicentre, phase 2 trial...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 23; no. 1; pp. 91 - 103
Main Authors:	Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, Neelapu, Sattva S
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.01.2022 Elsevier Limited
Series:	Lancet Oncol
Subjects:	Adverse events Aged Antigens Biological Products - adverse effects Biological Products - therapeutic use CD19 antigen CD20 antigen Cell therapy Chemotherapy Chimeric antigen receptors Clinical trials Cyclophosphamide Cytokines Female Fludarabine Hematology, Oncology, and Palliative Medicine Humans Immunotherapy, Adoptive Laboratories Leukapheresis Life Sciences Lymphocytes T Lymphoma Lymphoma, Non-Hodgkin - drug therapy Male Manufacturing Middle Aged Monoclonal antibodies Multiple organ dysfunction syndrome Non-Hodgkin's lymphoma Patients Recurrence Response rates United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!